Challenges with T1D or Insulin-Dependent Diabetes Most people are prescribed a GLP1 agonist for treating type 2 diabetes
In 2022, a novel GLP-1 analog, semaglutide was introduced as an anti-obesity drug
AG1 may also contribute a small amount of caffeine from matcha leaf powder and cocoa seed extract
10.1158/1541-7786.MCR-22-0509 169
*1 When looking at the efficacy regardless of if all patients stayed on treatment, an average weight loss of about 14% (13.6%) was achieved by people taking Wegovy pill compared to about 2% (2.4%) for placebo
Noteworthy, analyzing results according to baseline vasculogenic ED degree category, at study completion, IIEF-6 score was significantly increased in both subgroups of patients with mildmoderate and severe vasculogenic ED, whereas PSV was significantly increased only in the subgroup of patients with mildmoderate vasculogenic ED, despite a significantly lower baseline PSV in l-ARG compared to placebo group
